Revisiting PI3K Inhibitors for the Treatment of CLL:
Are They Living Up to Their Promise?
Recorded August 26, 2021
Co-Founder and Communications Director
Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd
Executive Vice President and Chief Medical Officer
Dr. Ian Flinn, MD, PhD is the Director of Lymphoma Research at the Sarah Cannon Research Institute. In this role, he oversees lymphoma research throughout Sarah Cannon and its affiliates. Dr. Flinn also serves as the director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology and TriStar Centennial Medical Center. Dr. Flinn’s research focuses on the development of new therapies for patients with lymphoma and chronic lymphocytic leukemia. This research includes first in human to phase 3 trials with novel approaches such as immune effector cell therapies, inhibitors of the B cell receptor pathway, and BCL-2 inhibitors amongst others. His research has been widely published in journals such as the New England Journal of Medicine, Lancet, Journal of Clinical Oncology and Blood.
Blocking the B-cell receptor (BCR) with ibrutinib and other BTKi drugs has revolutionized care in CLL. PI3K inhibitors also block that same receptor and are remarkably effective in treating CLL. Join Dr. Ian Flinn who will explain how these treatments work, the common side effects, and what role they might play in the future.
This program was made possible by grant support from Adaptive Biotechnologies and Bristol Myers Squibb
CLL Society Resources
- Normal Lab Values
- Keeping Track of Lab Results
- Test Before Treat™
- CLL Society Support Groups
- Sign up for CLL Society Alert Emails
- Things to Know About Idelalisib
- ASH 2019: Dr. Pagel Discusses Intermittent Dosing of PI3K Inhibitor ME401 in CLL
- ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an All-Oral Time-Limited Treatment for CLL